272 related articles for article (PubMed ID: 17545589)
1. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
[TBL] [Abstract][Full Text] [Related]
3. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
[TBL] [Abstract][Full Text] [Related]
5. Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.
Sirotnak FM; She Y; Khokhar NZ; Hayes P; Gerald W; Scher HI
Mol Carcinog; 2004 Nov; 41(3):150-63. PubMed ID: 15390081
[TBL] [Abstract][Full Text] [Related]
6. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja MJ; Savinainen KJ; Saramäki OR; Tammela TL; Vessella RL; Visakorpi T
Cancer Res; 2001 May; 61(9):3550-5. PubMed ID: 11325816
[TBL] [Abstract][Full Text] [Related]
7. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
8. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
9. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
11. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism of inhibiting the proliferation of prostate cancer by finasteride: a study using cDNA microarray].
Chen G; Geng J; Zhang YF
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1489-92. PubMed ID: 16061029
[TBL] [Abstract][Full Text] [Related]
13. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
[TBL] [Abstract][Full Text] [Related]
14. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
15. Gene amplifications associated with the development of hormone-resistant prostate cancer.
Edwards J; Krishna NS; Witton CJ; Bartlett JM
Clin Cancer Res; 2003 Nov; 9(14):5271-81. PubMed ID: 14614009
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor and prostate cancer: molecular aspects and gene expression profiling.
Sommer A; Haendler B
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):702-11. PubMed ID: 14579520
[TBL] [Abstract][Full Text] [Related]
17. Androgen-regulated gene expression in prostate cancer.
Trapman J; Cleutjens KB
Semin Cancer Biol; 1997 Feb; 8(1):29-36. PubMed ID: 9299579
[TBL] [Abstract][Full Text] [Related]
18. Reg IV: a promising marker of hormone refractory metastatic prostate cancer.
Gu Z; Rubin MA; Yang Y; Deprimo SE; Zhao H; Horvath S; Brooks JD; Loda M; Reiter RE
Clin Cancer Res; 2005 Mar; 11(6):2237-43. PubMed ID: 15788672
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Zhao H; Kim Y; Wang P; Lapointe J; Tibshirani R; Pollack JR; Brooks JD
Prostate; 2005 May; 63(2):187-97. PubMed ID: 15486987
[TBL] [Abstract][Full Text] [Related]
20. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
Shah RB; Mehra R; Chinnaiyan AM; Shen R; Ghosh D; Zhou M; Macvicar GR; Varambally S; Harwood J; Bismar TA; Kim R; Rubin MA; Pienta KJ
Cancer Res; 2004 Dec; 64(24):9209-16. PubMed ID: 15604294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]